Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010

Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010

Highlights ► Health problems detected were comparable with baseline data of the districts. ► Documented safety profile consistent with monovalent PS conjugate vaccine (ex: Hib). ► No outstanding safety issue with MenAfriVac ™. ► Hypersensitivity reactions require further assessment to rule out anaph...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2012-05, Vol.30, p.B46-B51
Hauptverfasser: Ouandaogo, Claude-Roger, Yaméogo, Téné M, Diomandé, Fabien V.K, Sawadogo, Charles, Ouédraogo, Bassirou, Ouédraogo-Traoré, Rasmata, Pezzoli, Lorenzo, Djingarey, Mamoudou H, Mbakuliyemo, Nehémie, Zuber, Patrick L.F
Format: Artikel
Sprache:eng
Schlagworte:
Adolescent
Adult
Adverse Drug Reaction Reporting Systems - organization & administration
AEFI
Africa
Allergy and Immunology
anaphylaxis
Burkina Faso - epidemiology
Child
Child, Preschool
Drug-Related Side Effects and Adverse Reactions - epidemiology
elderly
Female
fever
headache
Humans
Incidence
Infant
Male
Mass Vaccination - adverse effects
MenAfriVac
meningitis
Meningococcal Infections - epidemiology
Meningococcal Infections - prevention & control
Meningococcal Vaccines - administration & dosage
Meningococcal Vaccines - adverse effects
Meningococcal Vaccines - immunology
Monitoring
Neisseria meningitidis
people
Pharmacovigilance
Safety
seizures
urticaria
vaccination
Vaccine
vaccines
vomiting
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Highlights ► Health problems detected were comparable with baseline data of the districts. ► Documented safety profile consistent with monovalent PS conjugate vaccine (ex: Hib). ► No outstanding safety issue with MenAfriVac ™. ► Hypersensitivity reactions require further assessment to rule out anaphylactic reactions.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.12.112